Identification of intestinal biomarkers for evaluating disease activity in rheumatoid arthritis
Authors' conclusion
Intestinal barrier-related biomarkers are associated with disease activity in RA. The combined assessment of LBP, sCD14, and I-FABP demonstrates good performance in differentiating RA from HCs and in evaluating disease activity.
Study context
- Population
- Rheumatoid arthritis (RA) patients from three hospitals and healthy controls
- Participants
- 139 vs 52
- Comparison
- RA patients vs healthy controls
- RAn = 139
- Healthy controls (HCs)n = 52reference
- Outcome
- Predictive performance of combined intestinal barrier markers (LBP, sCD14, I-FABP) for diagnosing RA and evaluating disease activity
Methodological detailsmulticentre, three hospitals, ROC analysis
- Multicentre
- Three hospitals
- ROC analysis
Performance
As reported in the abstract
Combined LBP, sCD14 and I-FABP for distinguishing RA from HCs
AUC (p<0.001)
0.936
AUC for disease activity prediction
0.804
Further findings
sCD14 as independent predictor of synovitis
| OR (95% CI) | P value | ||
|---|---|---|---|
| sCD14 | 1.834 (1.160–2.901) | P = 0.009 | |
| 0.20.5125Odds ratio (log scale) |
sCD14 correlation with disease activity
- Positive correlation with DAS28-CRP
- P = 0.002
- Positive correlation with DAS28-ESR
- P = 0.048
- Positive correlation with inflammatory index
Intestinal fatty acid binding protein (I-FABP) association with DAS28-ESR
- Positive association with DAS28-ESR
- P = 0.027
Original publication
Identification of intestinal biomarkers for evaluating disease activity in rheumatoid arthritis. Clin Exp Rheumatol. Published 17 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →